Evidence map›Paper›PMID 36233576›Full record

ArticleJournal of clinical medicine2022

Survival of Breast Cancer by Stage, Grade and Molecular Groups in Mallorca, Spain.

Maria Clara Pascual, Juan José Montaño, Paula Franch, Carmen Sánchez-Contador, Maria Ramos

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maria Clara PascualDepartment of Psychology, University of Balearic Islands (UIB), 07122 Palma, Spain.
Juan José MontañoDepartment of Psychology, University of Balearic Islands (UIB), 07122 Palma, Spain.ORCID 0000-0002-1116-1964
Paula FranchHealth Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
Carmen Sánchez-ContadorHealth Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
Maria RamosHealth Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.ORCID 0000-0002-0903-5264
Health Research Institute of the Balearic Islands · ESUniversitat de les Illes Balears · ES

Funding

Instituto de Salud Carlos III PI14/01199
6 · The paper itself

Abstract

The aims of this study are: (1) to determine cause-specific survival by stage, grade, and molecular groups of breast cancer, (2) to identify factors which explain and predict the likelihood of survival and the risk of dying from this cancer; and (3) to find out the distribution of breast cancer cases by stage, grade, and molecular groups in females diagnosed in the period 2006-2012 in Mallorca (Spain). We collected data regarding age, date and diagnostic method, histology, laterality, sublocation, pathological or clinical tumor size (T), pathological or clinical regional lymph nodes (N), metastasis (M) and stage, histologic grade, estrogen and progesterone receptors status, HER-2 expression, Ki67 level, molecular classification, date of last follow-up or date of death, and cause of death. We identified 2869 cases. Cause-specific survival for the entire sample was 96% 1 year after diagnosis, 91% at 3 years and 87% at 5 years. Relative survival was 96.9% 1 year after diagnosis, 92.6% at 3 years and 88.5% at 5 years. The competing-risks regression model determined that patients over 65 years of age and patients with triple negative cancer have worse prognoses, and as stages progress, the prognosis for breast cancer worsens, especially from stage III.

Indexed as

breast cancercompeting-risks regression modelmultiple imputationsurvival

Identifiers

PMID36233576
PMCPMC9571737
OpenAlexW4297474379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.